年轻成人患者接受CD19 CAR-T细胞治疗的真实世界结局
该回顾性研究基于Pediatric Real-World CAR T Consortium与Real-World Outcomes of CAR T in Adult ALL协作组数据,描述70例18-26岁复发/难治B细胞急性淋巴细胞白血病年轻成人接受tisa-cel(n=50)或brexu-cel(n=20)的疗效与安全性;两种产品完全缓解率相似,12个月无复发生存率brexu-cel为46%、tisa-cel为36%,但brexu-cel的细胞因子释放综合征和免疫效应细胞相关神经毒性综合征发生率更高。
要点
- brexu-cel组细胞因子释放综合征发生率85%,高于tisa-cel组的56%。
- brexu-cel组免疫效应细胞相关神经毒性综合征发生率40%,高于tisa-cel组的18%。
- 多因素分析中低疾病负荷与总生存改善相关,CAR-T前使用inotuzumab与较差结局相关。
核心结论
- 年轻成人接受CD19 CAR-T的真实世界疗效在不同CAR-T产品间相当,但brexu-cel的毒性发生率似乎更高。
研究设计与样本
- 回顾性研究,利用Pediatric Real-World CAR T Consortium与Real-World Outcomes of CAR T in Adult ALL协作组的数据,纳入70例18-26岁接受商业CD19 CAR-T的年轻成人,其中tisa-cel组50例、brexu-cel组20例。
主要发现
- 细胞因子释放综合征发生率brexu-cel组85% vs tisa-cel组56%,免疫效应细胞相关神经毒性综合征发生率brexu-cel组40% vs tisa-cel组18%。
- 完全缓解率brexu-cel组80% vs tisa-cel组88%,两组相似。
- 12个月无复发生存率brexu-cel组46% vs tisa-cel组36%。
- 12个月以上缓解持久率brexu-cel组61% vs tisa-cel组41%。
- 12个月总生存率brexu-cel组84% vs tisa-cel组68%。
关键数值与推荐
- 多因素分析中,低疾病负荷与总生存改善相关,而CAR-T前使用inotuzumab与较差结局相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tisagenlecleucel (tisa-cel) and brexucabtagene autoleucel (brexu-cel) are approved CD19 chimeric antigen receptor T-cell therapy (CAR T) products for young adults (YA) with relapsed/refractory B-cell acute lymphoblastic leukemia. A distinct analysis of YAs receiving commercial CD19 CAR T has not been reported. Using retrospective data from the Pediatric Real-World CAR T Consortium and the Real-World Outcomes of CAR T in Adult ALL collaboration, we describe the efficacy and safety of tisa-cel and brexu-cel in 70 YAs (18-26 years; tisa-cel, n = 50; brexu-cel, n = 20). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were observed more frequently for brexu-cel vs tisa-cel (CRS, 85% vs 56%; ICANS, 40% vs 18%). Complete response rates were similar between products at 80% for brexu-cel and 88% for tisa-cel. Relapse-free survival (RFS) at 12 months was 46% for brexu-cel and 36% for tisa-cel. Durability of remission over 12 months was 61% for brexu-cel vs 41% for tisa-cel; 12-month overall survival (OS) for brexu-cel was 84% vs 68% for tisa-cel. In multivariate analysis, low disease burden was associated with improved OS, whereas inotuzumab before CAR T was associated with inferior outcomes. This study demonstrates comparable real-world efficacy among YAs receiving CD19 CAR T irrespective of CAR T construct; however, rates of toxicity seem higher with brexu-cel.
引用
- Lust H, Schultz LM, Kwon S, et al. Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy. Blood Adv. 2025. PMID: 40127395. doi:10.1182/bloodadvances.2024014846
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。